Search Results

AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.

The global viral vectors & plasmid DNA manufacturing market size reached USD 1,237.45 million in 2022 and is expected to surpass around USD 5,989.21 million by 2032

CANbridge Pharmaceuticals Inc. announced that data on the novel second-generation gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, will be presented at the American Society of Gene and Cell Therapy 26th Annual Meeting, May 16-20, Los Angeles, CA.

Tonix Pharmaceuticals Holding Corp. today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection.

CANbridge Pharmaceuticals Inc. announced that data on a novel second-generation spinal muscular atrophy gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, was presented as a poster at the American Society of Gene and Cell Therapy 26th Annual Meeting, in Los Angeles.

The global viral vectors and plasmids manufacturing market is expected to reach USD 1.12 billion by 2027.